1-(4-tert-Butyl-phenyl)-5-(pyridin-2-yloxy)-3-(3-trifluoromethyl-phenoxy)-1H-indole-2-carboxylic acid ethyl ester | 911847-06-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 1-(4-tert-Butyl-phenyl)-5-(pyridin-2-yloxy)-3-(3-trifluoromethyl-phenoxy)-1H-indole-2-carboxylic acid ethyl ester
• CAS: 911847-06-8
• 化学式: C₃₃H₂₉F₃N₂O₄
• 分子量: 574.599
• InChiKey: UKKWSVJDQYAICA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.1
• 重原子数：
  42.0
• 可旋转键数：
  7.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  62.58
• 氢给体数：
  0.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  1-(4-tert-Butyl-phenyl)-5-(pyridin-2-yloxy)-3-(3-trifluoromethyl-phenoxy)-1H-indole-2-carboxylic acid ethyl ester 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以90%的产率得到1-(4-tert-Butyl-phenyl)-5-(pyridin-2-yloxy)-3-(3-trifluoromethyl-phenoxy)-1H-indole-2-carboxylic acid
  参考文献：
  名称：

  Synthesis and biological activities of novel aryl indole-2-carboxylic acid analogs as PPARγ partial agonists

  摘要：

  A series of novel aryl indole-2-carboxylic acids has been identified as potent selective PPAR gamma modulators. Their chemical synthesis and in vitro activities are discussed. Compound 5 was selected for in vivo testing in the db/db mouse model of type 2 diabetes and resulted in reduction of hyperglycemia at comparable plasma exposure when compared to rosiglitazone. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.08.002
• 作为产物：
  描述：

  1-(4-tert-Butyl-phenyl)-3-hydroxy-5-methoxy-1H-indole-2-carboxylic acid ethyl ester 在 copper diacetate 、 三溴化硼 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 33.0h， 生成 1-(4-tert-Butyl-phenyl)-5-(pyridin-2-yloxy)-3-(3-trifluoromethyl-phenoxy)-1H-indole-2-carboxylic acid ethyl ester
  参考文献：
  名称：

  Synthesis and biological activities of novel aryl indole-2-carboxylic acid analogs as PPARγ partial agonists

  摘要：

  A series of novel aryl indole-2-carboxylic acids has been identified as potent selective PPAR gamma modulators. Their chemical synthesis and in vitro activities are discussed. Compound 5 was selected for in vivo testing in the db/db mouse model of type 2 diabetes and resulted in reduction of hyperglycemia at comparable plasma exposure when compared to rosiglitazone. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.08.002